BRIM Biotechnology, Inc. (TPE:6885)
Taiwan · Delayed Price · Currency is TWD 25.35
+0.20 (0.80%)
Sep 8, 2026, 1:30 PM CST
BRIM Biotechnology Revenue
BRIM Biotechnology had revenue of 3.97M TWD in the quarter ending June 30, 2026, with 151.71% growth. This brings the company's revenue in the last twelve months to 10.60M, up 427.82% year-over-year. In the year 2025, BRIM Biotechnology had annual revenue of 5.49M with 1,548.65% growth.
Revenue (ttm)
10.60M
Revenue Growth
+427.82%
P/S Ratio
315.59
Revenue / Employee
n/a
Employees
n/a
Market Cap
3.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.49M | 5.16M | 1,548.65% |
| Dec 31, 2024 | 333.00K | 243.00K | 270.00% |
| Dec 31, 2023 | 90.00K | -436.00K | -82.89% |
| Dec 31, 2022 | 526.00K | 166.00K | 46.11% |
| Dec 31, 2021 | 360.00K | -90.41M | -99.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 467.69M |
| BioGend Therapeutics | 236.58M |
| Formosa Pharmaceuticals | 52.59M |
| OBI Pharma | 52.20M |
| Shine-On BioMedical | 50.62M |